Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diclofenac + paracetamol is a fixed-dose combination of two small molecule drugs used for pain relief and inflammation. Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase (COX)-1 and COX-2 enzymes, thereby reducing the synthesis of prostaglandins responsible for pain, fever, and inflammation. Paracetamol (also known as acetaminophen) acts as an analgesic and antipyretic by inhibiting prostaglandin synthesis in the central nervous system. The combination provides enhanced pain relief compared to either agent alone. It is primarily indicated for conditions such as headache, mild migraine, muscle pain, dental pain, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, painful menses, musculoskeletal joint conditions, skeletal muscle spasms, toothache, ear pain and backache[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diclofenac + paracetamol.